Oragenics (Oragenics) EBIT per Share : $-7.97 (TTM As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Oragenics EBIT per Share?

Oragenics's EBIT per Share for the three months ended in Mar. 2024 was $-0.70. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-7.97.

During the past 3 years, the average EBIT per Share Growth Rate was 31.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 30.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Oragenics's EBIT per Share or its related term are showing as below:

OGEN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 3.9 Med: 29.25 Max: 49.1
Current: 31

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Oragenics was 49.10% per year. The lowest was 3.90% per year. And the median was 29.25% per year.

OGEN's 3-Year EBIT Growth Rate is ranked better than
81.5% of 1303 companies
in the Biotechnology industry
Industry Median: 3.6 vs OGEN: 31.00

Oragenics's EBIT for the three months ended in Mar. 2024 was $-2.44 Mil.

Oragenics EBIT per Share Historical Data

The historical data trend for Oragenics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oragenics EBIT per Share Chart

Oragenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-22.07

-28.05

-8.08

-7.11

-9.17

Oragenics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-1.29	-1.51	-0.85	-4.92	-0.70

Oragenics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Oragenics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-20.625	/	2.250
=	-9.17

Oragenics's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.444	/	3.496
=	-0.70

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.97

Oragenics (AMEX:OGEN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Oragenics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Oragenics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Oragenics (Oragenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oragenics Inc (AMEX:OGEN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

0A64:UK

Address

4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634

Website

https://www.oragenics.com

Oragenics Inc is engaged in research and the development of potential therapies to fight infectious diseases including coronaviruses and multidrug-resistant organisms. Its product (NT-CoV2-1) is an intranasal vaccine candidate to prevent coronavirus disease ("COVID-19") from the SARS-CoV-2 virus and variants thereof. Its focus on developing vaccines and novel antibiotics It is also developing a Terra CoV-2 immunization product candidate to combat the novel coronavirus.

Executives

Fred Telling	director	501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119
John P Gandolfo	director	62 TERRACE ROAD, WAYNE NJ 07470
Cassidy Bruce A. Sr.	director	C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203
Janet Huffman	officer: CFO, Secretary and Treasurer	5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232
Robert C Koski	director, 10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Michael O'keefe Sullivan	officer: CFO, Secretary and Treasurer	3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607
Joseph Hernandez	10 percent owner	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Kimberly M Murphy	director	101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Koski Family Lp	10 percent owner	1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Alan Joslyn	director, officer: CEO and President	39 OLD RIDGEBURY ROAD, DANBURY CT 06810
Charles L Pope	director	4902 EISENHOWER BOULEVARD, TAMPA FL 33634
Christine L Koski	director, 10 percent owner	1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243
Beverly Koski	10 percent owner
Thomas L Koski	10 percent owner